Month: April 2022
XL114 is a CARD11-BCL10-MALT1 pathway inhibitor with demonstrated activity in lymphoma models that are resistant to Bruton’s tyrosine kinase inhibitors – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Apr. 14, 2022– Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114, a novel anti-cancer compound that inhibits the…
Read More
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with navicixizumab-paclitaxel combination in heavily pretreated platinum-resistant ovarian cancer patients Xerna™ TME Panel shows enhanced response in biomarker positive (62%) vs. biomarker negative patients (25%) Results support co-development of navicixizumab and Xerna TME Panel in ovarian cancer Excerpt from the…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, April 13, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy…
Read More
Excerpt from the Press Release: HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinical trial of XW004. XW004 is an oral tablet formulation of Ecnoglutide, a novel…
Read More
– Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors – Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a novel mechanism – Loading CAR T cells with pelareorep led to dramatic improvements in their persistence and anti-cancer activity as…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the…
Read More
Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer Excerpt from the Press Release: CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies…
Read More
Full Phase 1 data analysis of VE303, a defined bacterial consortium candidate for C. difficile infection, published in Cell Host & Microbe Positive topline Phase 2 results for VE303 announced in 2021; Phase 3 preparations underway Acceptance of three abstracts for podium presentations at Digestive Disease Week 2022 Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences, a…
Read More
In a phase 2a study, CHOP researchers showed exendin-(9-39) leads to blood sugar control in children with HI, which could improve care for a rare condition with few treatments Excerpt from the Press Release: PHILADELPHIA, April 13, 2022 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) have shown that a targeted treatment they developed is effective at controlling…
Read More
Results demonstrate safety and efficacy of ZTALMY, first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years and older Excerpt from the Press Release: RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that The Lancet Neurology has publishedresults from the…
Read More